On October 9, HENGRUI PHARMA fell 3.43% in regular trading, trading at HK$46.78 with turnover of HK$110 million. The decline came despite the company's recent positive catalysts, including EMA acceptance of its fluazolepali capsule marketing application and progress on A-share buybacks, as the broader Hong Kong pharmaceutical sector experienced a broad risk-off pullback.

Within the Pharmaceuticals sector, overall sentiment was weak, with CSPC PHARMA down 2.96%, HANSOH PHARMA down 2.18%, SBP GROUP down 2.10%, ASYMCHEM down 6.99%, and HUTCHMED down 1.58%. The stock followed the sector lower in the absence of any direct negative company-specific news.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based company primarily engaged in the research, development, production, and sale of pharmaceuticals. The company focuses on the oncology field, covering kinase inhibitors, antibody-drug conjugates (ADC), tumor immunity, hormone receptor regulation, DNA repair and epigenetics, and supportive care research areas. Its products include anti-tumor, analgesic anesthesia, and contrast agents, applied in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology. The company mainly conducts its business in domestic and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)